title: Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination.
abstract: OBJECTIVE
  To report a case of delayed methotrexate (MTX) elimination while receiving concomitant levetiracetam.
  
  
  METHODS
  A 46-year-old man with relapsed osteosarcoma of the base of the skull receiving high-dose MTX tolerated his first cycle of MTX with elimination to nontoxic MTX levels (≤0.1 µmol/L) within 90 hours. After hospital discharge, the patient experienced seizures secondary to brain metastasis and started on levetiracetam, which was continued as maintenance therapy. The patient experienced delayed MTX elimination during cycles 2, 3, and 4 while receiving levetiracetam. On average, elimination to nontoxic MTX levels took 130 hours (106-144 hours). Before the fifth cycle of MTX, lorazepam was substituted for the levetiracetam. MTX was eliminated to nontoxic levels within 95 hours. During all cycles, the patient received standard supportive care and serum creatinine remained stable. No other drugs known to interact with MTX were administered.
  
  
  CONCLUSIONS
  This possible drug interaction has only been reported once in the pediatric population. With a score of 6 on the Drug Interaction Probability Scale for evaluating causation of drug interactions, it is probable that the delayed MTX elimination was caused by an interaction with levetiracetam.
  
  
  CONCLUSIONS
  Coadministration of levetiracetam and MTX may result in delayed elimination of MTX, increasing the likelihood of toxicity. Consideration should be given to temporarily switching from levetiracetam to another antiepileptic (ie, lorazepam) to prevent this interaction. This is particularly important in those experiencing delayed elimination with prior cycles of concomitant MTX and levetiracetam or those at greater risk for MTX toxicity.
authors.affiliation: St Vincent Hospital, Indianapolis, IN, USA.
authors.forename: Emily
authors.initials: E
authors.lastname: Bain
authors.forename: Ruemu E
authors.initials: RE
authors.lastname: Birhiray
authors.forename: David J
authors.initials: DJ
authors.lastname: Reeves
mesh_terms: D000927:Anticonvulsants / Q000008:administration & dosage*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D004347:Drug Interactions; D006801:Humans; D000077287:Levetiracetam; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D012516:Osteosarcoma / Q000188:drug therapy* / Q000378:metabolism; D010889:Piracetam / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000927:Anticonvulsants; D000964:Antimetabolites, Antineoplastic; D000077287:Levetiracetam; D008727:Methotrexate; D010889:Piracetam
keywords: interaction; levetiracetam; methotrexate